Curant Health’s Patient Fulfillment Model and its Impact on Medication Adherence for IBD Patients at Johns Hopkins University

Dr. Sharon Dudley-Brown and Vickie Andros, PharmD, present study results at ACG 2016

 At Curant Health, proving the value of our medication therapy management protocols and patient support services is paramount to our mission of improving lives and outcomes for patients with chronic conditions.

 As such, we want to express enthusiastic congratulations to Dr. Sharon Dudley-Brown, Principal Investigator and Assistant Professor of Medicine at Johns Hopkins University and our Director of Clinical Services, Vickie Andros, PharmD.  Dudley-Brown,  Andros and Krystin Tran, PharmD. recently had their Project A.L.I.V.E. poster accepted for the American College of Gastroenterology 2016 Annual Scientific Meeting. They will present interim study results at ACG 2016 on Monday, October 17, 2016.

 “Do you take your IBD medicine? Assessing the effect of a patient fulfillment model on medication adherence.”

About Project A.L.I.V.E

Project A.L.I.V.E (Adherence and Long-Term IBD Value-Added Effectiveness) seeks to “implement and evaluate the effectiveness of an Inflammatory Bowel Disease (IBD) Medication Therapy Management (MTM) patient fulfillment model compared to standard care in a large university hospital setting.”

“Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, debilitating conditions that can have important economic and clinical implications,” said Dr. Dudley-Brown. “In 2004, the annual cost of IBD in the United States was estimated at $1.84 billion. IBD is associated with high morbidity, loss of work productivity and impaired quality of life.”

According to the study abstract, the absence of an integrated MTM platform in IBD care limits the ability to track and fully understand patient outcomes including Adverse Drug Events (ADE’s), hospital readmissions and long-term adherence rates. Systematic review of the literature validates there is no reported long term adherence data for CD or UC.  Likewise, no data has been published evaluating the impact of MTM on IBD outcomes. Read more.

Results to date

As published in the March 2016 edition of Inflammatory Bowel Diseases, the official journal of the Crohn’s & Colitis Foundation of America, “As this study is ongoing, we will present demographic findings as well as any noted trends. To date, 57 subjects have been enrolled in the study: 21 in the intervention arm, 19 in control arm 1, and 17 in control arm 2. The population was young and mostly female, with mean age of 38.8 years. Only 1 patient was identified as a smoker. Thirty subjects (52.6%) are receiving biologic therapy. Mean baseline DISQ and SIBDQ scores were 27.9 and 53.4, respectively, indicating good baseline symptom control.”

 We can’t wait to see the results delivered by Dr. Dudley-Brown and Dr. Andros to the leading gastroenterologists and associated researchers and clinicians at ACG 2016 in Las Vegas.

Connect

Connect with us by following @curanthealth, on LinkedIn and onsite at ACG 2016. If you would like to learn more about our medication management protocols and patient support services proven to improve adherence, outcomes and lives for chronically ill patients including those suffering from IBD, contact: Jake Caines, Director of Client Strategy and Performance at jcaines@curanthealth.com.

 
EmailEmailEmailEmail